These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

409 related articles for article (PubMed ID: 12579258)

  • 1. Comparative analysis of K-ras point mutation, telomerase activity, and p53 overexpression in pancreatic tumours.
    Uemura K; Hiyama E; Murakami Y; Kanehiro T; Ohge H; Sueda T; Yokoyama T
    Oncol Rep; 2003; 10(2):277-83. PubMed ID: 12579258
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mucin gene expression in intraductal papillary-mucinous pancreatic tumours and related lesions.
    Terris B; Dubois S; Buisine MP; Sauvanet A; Ruszniewski P; Aubert JP; Porchet N; Couvelard A; Degott C; Fléjou JF
    J Pathol; 2002 Aug; 197(5):632-7. PubMed ID: 12210083
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pancreatic tumours: molecular pathways implicated in ductal cancer are involved in ampullary but not in exocrine nonductal or endocrine tumorigenesis.
    Moore PS; Orlandini S; Zamboni G; Capelli P; Rigaud G; Falconi M; Bassi C; Lemoine NR; Scarpa A
    Br J Cancer; 2001 Jan; 84(2):253-62. PubMed ID: 11161385
    [TBL] [Abstract][Full Text] [Related]  

  • 4. p16 and p53 gene alterations and accumulations in the malignant evolution of intraductal papillary-mucinous tumors of the pancreas.
    Wada K
    J Hepatobiliary Pancreat Surg; 2002; 9(1):76-85. PubMed ID: 12021900
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Progressive genomic alterations in intraductal papillary mucinous tumours of the pancreas and morphologically similar lesions of the pancreatic ducts.
    Soldini D; Gugger M; Burckhardt E; Kappeler A; Laissue JA; Mazzucchelli L
    J Pathol; 2003 Apr; 199(4):453-61. PubMed ID: 12635136
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differential roles of alterations of p53, p16, and SMAD4 expression in the progression of intraductal papillary-mucinous tumors of the pancreas.
    Sasaki S; Yamamoto H; Kaneto H; Ozeki I; Adachi Y; Takagi H; Matsumoto T; Itoh H; Nagakawa T; Miyakawa H; Muraoka S; Fujinaga A; Suga T; Satoh M; Itoh F; Endo T; Imai K
    Oncol Rep; 2003; 10(1):21-5. PubMed ID: 12469138
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clonality and K-ras mutation analyses of epithelia in intraductal papillary mucinous tumor and mucinous cystic tumor of the pancreas.
    Yoshizawa K; Nagai H; Sakurai S; Hironaka M; Morinaga S; Saitoh K; Fukayama M
    Virchows Arch; 2002 Nov; 441(5):437-43. PubMed ID: 12447672
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ki-ras codon 12 point mutation and p53 mutation in pancreatic diseases.
    Yamaguchi K; Chijiiwa K; Noshiro H; Torata N; Kinoshita M; Tanaka M
    Hepatogastroenterology; 1999; 46(28):2575-81. PubMed ID: 10522044
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MUC1 overexpression is the most reliable marker of invasive carcinoma in intraductal papillary-mucinous tumor (IPMT).
    Ueda M; Miura Y; Kunihiro O; Ishikawa T; Ichikawa Y; Endo I; Sekido H; Togo S; Shimada H
    Hepatogastroenterology; 2005; 52(62):398-403. PubMed ID: 15816444
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunohistochemical expression of 14-3-3 sigma protein in intraductal papillary-mucinous tumor and invasive ductal carcinoma of the pancreas.
    Okada T; Masuda N; Fukai Y; Shimura T; Nishida Y; Hosouchi Y; Kashiwabara K; Nakajima T; Kuwano H
    Anticancer Res; 2006; 26(4B):3105-10. PubMed ID: 16886641
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intraductal papillary-mucinous tumours represent a distinct group of pancreatic neoplasms: an investigation of tumour cell differentiation and K-ras, p53 and c-erbB-2 abnormalities in 26 patients.
    Sessa F; Solcia E; Capella C; Bonato M; Scarpa A; Zamboni G; Pellegata NS; Ranzani GN; Rickaert F; Klöppel G
    Virchows Arch; 1994; 425(4):357-67. PubMed ID: 7820300
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Telomerase activity is a useful marker to distinguish malignant pancreatic cystic tumors from benign neoplasms and pseudocysts.
    Yeh TS; Cheng AJ; Chen TC; Jan YY; Hwang TL; Jeng LB; Chen MF; Wang TC
    J Surg Res; 1999 Dec; 87(2):171-7. PubMed ID: 10600346
    [TBL] [Abstract][Full Text] [Related]  

  • 13. P53 mutation but not p16/MTS1 mutation occurs in intraductal papillary mucinous tumors of the pancreas.
    Mueller J; Gansauge S; Mattfeldt T
    Hepatogastroenterology; 2003; 50(50):541-4. PubMed ID: 12749268
    [TBL] [Abstract][Full Text] [Related]  

  • 14. K-Ras and microsatellite marker analysis of fine-needle aspirates from intraductal papillary mucinous neoplasms of the pancreas.
    Schoedel KE; Finkelstein SD; Ohori NP
    Diagn Cytopathol; 2006 Sep; 34(9):605-8. PubMed ID: 16900481
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New classification of pancreatic intraductal papillary-mucinous tumour by mucin expression: its relationship with potential for malignancy.
    Nakamura A; Horinouchi M; Goto M; Nagata K; Sakoda K; Takao S; Imai K; Kim YS; Sato E; Yonezawa S
    J Pathol; 2002 Jun; 197(2):201-10. PubMed ID: 12015744
    [TBL] [Abstract][Full Text] [Related]  

  • 16. p53 protein expression in intraductal papillary mucinous tumors (IPMT) of the pancreas as an indicator of tumor malignancy.
    Kawahira H; Kobayashi S; Kaneko K; Asano T; Ochiai T
    Hepatogastroenterology; 2000; 47(34):973-7. PubMed ID: 11020860
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ductal neoplasia of the pancreas: nosologic, clinicopathologic, and biologic aspects.
    Adsay NV; Basturk O; Cheng JD; Andea AA
    Semin Radiat Oncol; 2005 Oct; 15(4):254-64. PubMed ID: 16183479
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunohistochemical analysis of molecular biological factors in intraductal papillary-mucinous tumors and mucinous cystic tumors of the pancreas.
    Sawai H; Okada Y; Funahashi H; Matsuo Y; Tanaka M; Manabe T
    Scand J Gastroenterol; 2004 Nov; 39(11):1159-65. PubMed ID: 15545177
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increased K-ras mutation and expression of S100A4 and MUC2 protein in the malignant intraductal papillary mucinous tumor of the pancreas.
    Jang JY; Park YC; Song YS; Lee SE; Hwang DW; Lim CS; Lee HE; Kim WH; Kim SW
    J Hepatobiliary Pancreat Surg; 2009; 16(5):668-74. PubMed ID: 19412570
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The potential diagnostic use of K-ras codon 12 and p53 alterations in brush cytology from the pancreatic head region.
    Sturm PD; Hruban RH; Ramsoekh TB; Noorduyn LA; Tytgat GN; Gouma DJ; Offerhaus GJ
    J Pathol; 1998 Nov; 186(3):247-53. PubMed ID: 10211112
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.